A Phase 3 interventional study of ProQuad® and Infanrix® hexa in Varicella, Measles and Mumps, sponsored by Merck Sharp & Dohme LLC. Completed at 50 sites in 2 countries. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-19.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing measles, mumps, rubella, varicella vaccine in Chickenpox — none open to participants now, none under way, none of them phase 3. measles, mumps, rubella, varicella vaccine · Chickenpox.
Among the 11 studies testing measles, mumps, rubella, varicella vaccine in Chickenpox, this one is the 7th largest by enrollment, is one of 3 that started in 2007, is one of 9 in phase 3, and was the 4th registered.
180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.
Browse Chickenpox studies →None of the 11 studies testing measles, mumps, rubella, varicella vaccine in Chickenpox is open now. The open studies under Chickenpox, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 12 Months to 23 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2007.
This study's enrollment of 955 is above the median of 475 across 149 interventional studies indexed under Chickenpox.
Median enrollment 1,027 across the 11 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
28 studies in Chickenpox by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 27 finished, 19 (70%) have results posted.
Among the 28 studies in Chickenpox by Merck & Co., Inc, this one is the 12th largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2007, is one of 21 in phase 3, and was the 7th registered.
Merck & Co., Inc’s Chickenpox studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing measles, mumps, rubella, varicella vaccine in Chickenpox, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 28 in Chickenpox:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric (12 to 23 months of age) participants received ProQuad® and Infanrix® hexa (booster dose) concomitantly on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
Biological: ProQuad® · Biological: Infanrix® hexa
Pediatric (12 to 23 months of age) participants received ProQuad® on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
Biological: ProQuad®
Pediatric (12 to 23 months of age) participants received Infanrix® hexa (booster dose) on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
Biological: Infanrix® hexa
Participants received a 0.5 mL subcutaneous injection of ProQuad® containing the following live attenuated virus strains: measles virus Enders' Edmonston strain (≥3.00 log10 50% cell culture infectious dose \[CCID\]50), mumps virus Jeryl Lynn™ (Level B) strain (≥4.30 log10 CCID50), rubella virus Wistar RA 27/3 strain (≥3.00 log10 CCID50), and varicella virus Oka/Merck strain (≥3.99 log10 plaque-forming units \[PFU\]).
Participants received a 0.5 mL intramuscular injection of Infanrix® hexa containing the following: diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), 3-component acellular pertussis (pertussis taxoid, filamentous haemagglutinin, and pertactin) (25 ug), Hepatitis B surface antigen recombinant (S protein) (10 ug), inactivated poliovirus types 1-3 (type 1: 40 D-antigen units; type 2: 8 D-antigen units; type 3: 32 D-antigen units), and Haemophilus influenzae type B (Hib) polysaccharide conjugate to tetanus toxoid (20-40 ug).
Percentage of Participants Meeting Antibody Response Rate Criteria to Measles, Mumps, Rubella, and Varicella
The percentage of participants with seronegative baseline values who met antibody response criteria in Arm 1: ProQuad® + Infanrix® hexa and Arm 2: ProQuad® was determined. Post-vaccination antibody response and baseline seronegativity criteria were as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre \<255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre \<10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre \<10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre \<1.25 gpELISA units/mL. Measles, mumps and rubella antibody levels were determined using enzyme-linked immunosorbent assay (ELISA) and varicella antibody levels were determined with glycoprotein-based ELISA (gpELISA).
Time frame: Day 42
Percentage of Participants Meeting Post-vaccination Antibody Response Rates to Hepatitis B and Haemophilus Influenzae Type B
The percentage of participants with seronegative baseline values who met antibody response criteria in Arm 1: ProQuad® + Infanrix® hexa and Arm 3: Infanrix® hexa was determined. Post-vaccination antibody response and baseline seronegativity criteria were as follows: Hepatitis B antibody titre ≥10 IU/mL and Haemophilus Influenzae Type b antibody titre ≥1 ug/mL. Hepatitis B antibody levels were determined using anti-HBs ORTHO ECi Immunodiagnostic Assay. Haemophilus Influenzae Type b antibody (anti-polyribosylribitol phosphate \[PRP\]) levels were determined with radioimmunoassay (RIA) or with enzyme immunoassay (EIA).
Time frame: Day 42
Post-vaccination Geometric Mean Titres (GMT) to Pertussis
The GMT to pertussis were compared in Arm1: ProQuad® + Infanrix® hexa and Arm 3: Infanrix® hexa. Anti-pertussis toxin (anti-PT), anti-filamentous hemagglutinin (anti-FHA), and anti-pertactin (anti-PRN) were determined using ELISA on solid phase based on sandwich principle.
Time frame: Day 42
A total of 963 participants were screened at study centers in Italy and Germany.
| Milestone | Arm 1: ProQuad® + Infanrix® Hexa | Arm 2: ProQuad® | Arm 3: Infanrix® Hexa |
|---|---|---|---|
| Started | 479 | 235 | 241 |
| Vaccinated | 477 | 235 | 240 |
| Completed | 472 | 234 | 239 |
| Not completed | 7 | 1 | 2 |
| Withdrew: Protocol violation | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 5 | 1 | 0 |
The percentage of participants with seronegative baseline values who met antibody response criteria in Arm 1: ProQuad® + Infanrix® hexa and Arm 2: ProQuad® was determined. Post-vaccination antibody response and baseline seronegativity criteria were as follows: measles antibody titre ≥255 mIU/mL in participants with baseline titre \<255 mIU/mL; mumps antibody titre ≥10 ELISA Ab units/mL in participants with baseline titre \<10 ELISA Ab units mL; rubella antibody titre ≥10 IU/mL in participants with baseline titre \<10 IU/mL; varicella antibody titre ≥5 gpELISA units/mL in participants with baseline titre \<1.25 gpELISA units/mL. Measles, mumps and rubella antibody levels were determined using enzyme-linked immunosorbent assay (ELISA) and varicella antibody levels were determined with glycoprotein-based ELISA (gpELISA).
| Percentage of Participants | Arm 1: ProQuad® + Infanrix® Hexa | Arm 2: ProQuad® |
|---|---|---|
| Measles | 97.4 (95.4 to 98.7) | 96.3 (92.8 to 98.4) |
| Mumps | 96.7 (94.6 to 98.2) | 98.6 (95.9 to 99.7) |
| Rubella | 97.9 (96.1 to 99.0) | 99.1 (96.7 to 99.9) |
| Varicella | 97.7 (95.7 to 99.0) | 95.1 (91.2 to 97.6) |
The percentage of participants with seronegative baseline values who met antibody response criteria in Arm 1: ProQuad® + Infanrix® hexa and Arm 3: Infanrix® hexa was determined. Post-vaccination antibody response and baseline seronegativity criteria were as follows: Hepatitis B antibody titre ≥10 IU/mL and Haemophilus Influenzae Type b antibody titre ≥1 ug/mL. Hepatitis B antibody levels were determined using anti-HBs ORTHO ECi Immunodiagnostic Assay. Haemophilus Influenzae Type b antibody (anti-polyribosylribitol phosphate \[PRP\]) levels were determined with radioimmunoassay (RIA) or with enzyme immunoassay (EIA).
| Percentage of participants | Arm 1: ProQuad® + Infanrix® Hexa | Arm 3: Infanrix® Hexa |
|---|---|---|
| Hepatitis B | 99.5 (98.3 to 99.9) | 98.1 (95.3 to 99.5) |
| Haemophilus Influenzae Type B | 98.2 (96.3 to 99.3) | 95.3 (91.5 to 97.7) |
The GMT to pertussis were compared in Arm1: ProQuad® + Infanrix® hexa and Arm 3: Infanrix® hexa. Anti-pertussis toxin (anti-PT), anti-filamentous hemagglutinin (anti-FHA), and anti-pertactin (anti-PRN) were determined using ELISA on solid phase based on sandwich principle.
| GMT (IU/mL) | Arm 1: ProQuad® + Infanrix® Hexa | Arm 3: Infanrix® Hexa |
|---|---|---|
| Anti-PT GMT | 132.6 (123.8 to 142.0) | 139.1 (126.7 to 152.8) |
| Anti-FHA GMT | 210.9 (195.7 to 227.2) | 189.9 (170.2 to 211.8) |
| Anti-PRN GMT | 310.0 (282.2 to 340.7) | 259.7 (226.3 to 298.1) |
Collected over Up to Day 42. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: ProQuad® + Infanrix® Hexa | — | 7/474 (1.5%) | 409/474 (86.3%) |
| Arm 2: ProQuad® | — | 6/234 (2.6%) | 134/234 (57.3%) |
| Infanrix® Hexa | — | 4/239 (1.7%) | 184/239 (77%) |
| Event | Arm 1: ProQuad® + Infanrix® Hexa | Arm 2: ProQuad® | Infanrix® Hexa |
|---|---|---|---|
| BronchitisInfections and infestations | 0/474 | 3/234 | 1/239 |
| BronchopneumoniaInfections and infestations | 1/474 | 1/234 | 0/239 |
| Conjunctivitis bacterialInfections and infestations | 0/474 | 1/234 | 0/239 |
| Gastroenteritis rotavirusInfections and infestations | 1/474 | 1/234 | 1/239 |
| Upper respiratory tract infectionInfections and infestations | 0/474 | 1/234 | 0/239 |
| Febrile convulsionNervous system disorders | 2/474 | 0/234 | 0/239 |
| InfluenzaInfections and infestations | 0/474 | 0/234 | 1/239 |
| Electric shockInjury, poisoning and procedural complications | 0/474 | 0/234 | 1/239 |
| GastroenteritisInfections and infestations | 1/474 | 0/234 | 0/239 |
| Otitis mediaInfections and infestations | 1/474 | 0/234 | 0/239 |
| Event | Arm 1: ProQuad® + Infanrix® Hexa | Arm 2: ProQuad® | Infanrix® Hexa |
|---|---|---|---|
| Injection site erythemaGeneral disorders | 274/474 | 31/234 | 126/239 |
| Injection site swellingGeneral disorders | 203/474 | 7/234 | 93/239 |
| Injection site painGeneral disorders | 198/474 | 33/234 | 84/239 |
| PyrexiaGeneral disorders | 184/474 | 80/234 | 68/239 |
| NasopharyngitisInfections and infestations | 48/474 | 14/234 | 18/239 |
| RhinitisInfections and infestations | 27/474 | 20/234 | 9/239 |
| Rash morbilliformSkin and subcutaneous tissue disorders | 33/474 | 16/234 | 5/239 |
| CoughRespiratory, thoracic and mediastinal disorders | 31/474 | 13/234 | 11/239 |
| DiarrhoeaGastrointestinal disorders | 22/474 | 14/234 | 14/239 |
| VomitingGastrointestinal disorders | 14/474 | 2/234 | 14/239 |
| Age, Continuous(Months) | Arm 1: ProQuad® + Infanrix® Hexa | Arm 2: ProQuad® | Arm 3: Infanrix® Hexa | Total |
|---|---|---|---|---|
| Mean | 13.6 ± 1.9 | 13.4 ± 1.5 | 13.5 ± 1.7 | 13.5 ± 1.7 |
| Sex: Female, Male(Participants) | Arm 1: ProQuad® + Infanrix® Hexa | Arm 2: ProQuad® | Arm 3: Infanrix® Hexa | Total |
|---|---|---|---|---|
| Female | 222 | 112 | 114 | 448 |
| Male | 257 | 123 | 127 | 507 |
Plan to share: No
Ran from Jan 2007 to primary completion in Mar 2008, 14 months.
Results were first posted in Mar 2018, 9 years 11 months after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Chickenpox, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 15. This study's 14 months is above that.
Counting every sponsor, half of 39 studies reached it within 13 months; a quarter within 9 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Measles, mumps, rubella, varicella vaccine · Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine